Results 201 to 210 of about 59,389 (246)

Phenylbutyrate Attenuates the Expression of Bcl-XL, DNA-PK, Caveolin-1, and VEGF in Prostate Cancer Cells

, 2001
Meidee Goh, Feng Chen, Michelle T. Paulsen, Ann M. Yeager, Erica S. Dyer, Mats Ljungman   +5 more
openalex   +1 more source

Targeting Bcl-xL with Navitoclax Effectively Eliminates Senescent Tumor Cells That Appear Following CEP-1347-Induced Differentiation of Glioma Stem Cells. [PDF]

Int J Mol Sci
Takenouchi S, Ito Y, Nakamura K, Nakagawa-Saito Y, Mitobe Y, Togashi K, Suzuki S, Sugai A, Sonoda Y, Kitanaka C, Okada M.   +10 more
europepmc   +1 more source

Mevalonate pathway activation in Ewing sarcoma reveals a 3D-specific synergy between statins and BCL-xL inhibition

Radic-Sarikas B, Markovic M, Sturtzel C, Ilg M, Zylka MM, Surdez D, Metzelder M, Distel M, Ovsianikov A, Halbritter F, Kovar H.   +10 more
europepmc   +1 more source

Bcl-xL overexpression in T cells preserves muscle mitochondrial structure and function and prevents frailty in old mice. [PDF]

Sci Adv
Mas-Bargues C, Román-Domínguez A, Sanz-Ros J, Romero-García N, Huete-Acevedo J, Dromant M, Cuervo AM, Borrás C, Viña J.   +8 more
europepmc   +1 more source

Eukaryotic initiation factor 3F (eIF3F) regulates the IRES-mediated translation of Bcl-xL via its interaction with programmed cell death 4 (PDCD4) protein [PDF]

Veda Hegde, Divya Sharma, Harshil Patel, Pavan Narasimha, Jason Luddu, Martin Holčı́k, Nehal Thakor   +6 more
openalex   +1 more source

A novel regimen for pancreatic ductal adenocarcinoma targeting MEK, BCL-xL, and EGFR. [PDF]

Neoplasia
Han S, Tushoski-Alemán GW, Zhang P, Zheng G, Zhou D, Huo Z, Licht J, George TJ, Allegra C, Trevino JG, Hughes SJ.   +10 more
europepmc   +1 more source

Efficacy of a novel BCL-xL degrader, DT2216, in preclinical models of JAK2-mutated post-MPN AML.

Blood
Wang Z, Skwarska A, Poigaialwar G, Chaudhry S, Rodriguez-Meira A, Sui P, Olivier E, Jia Y, Gupta V, Fiskus W, Ramage CL, Zheng G, Schurer A, Gritsman K, Papapetrou EP, Bhalla K, Zhou D, Mead AJ, Rampal RK, Tyner JW, Abbas HA, Pemmaraju N, Tatarata QZ, Konopleva M.   +23 more
europepmc   +1 more source

Discovery of PZ671, a highly potent and <i>in vivo</i> active CRBN-recruiting Bcl-xL degrader. [PDF]

RSC Med Chem
Zhang P, Thummuri D, Hu W, Khan S, He Y, Zhang X, Pal P, Lv D, Zhou D, Zheng G.   +9 more
europepmc   +1 more source

Bcl-xL is translocated to the nucleus via CtBP2 to epigenetically promote metastasis. [PDF]

Cancer Lett
Zhang T, Li S, Tan YA, Chen X, Zhang C, Chen Z, Mishra B, Na JH, Choi S, Shin SJ, Damle P, Chougoni KK, Grossman SR, Wang D, Jiang X, Li Y, Hissong E, Chen YT, Xiang JZ, Du YN.   +19 more
europepmc   +1 more source

Déterminants moléculaires non-apoptotiques de l'activité oncogénique de Bcl-xL : rôle de la monodéamidation de Bcl-xL

, 2017
Mohamad El Dhaybi
openalex   +1 more source